NZ599132A - Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists - Google Patents
Indazole and pyrazolopyridine compounds as ccr1 receptor antagonistsInfo
- Publication number
- NZ599132A NZ599132A NZ599132A NZ59913210A NZ599132A NZ 599132 A NZ599132 A NZ 599132A NZ 599132 A NZ599132 A NZ 599132A NZ 59913210 A NZ59913210 A NZ 59913210A NZ 599132 A NZ599132 A NZ 599132A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fluoro
- phenyl
- indazole
- pyrazolo
- cyclopropyl
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title abstract 2
- 102000004500 CCR1 Receptors Human genes 0.000 title abstract 2
- 108010017319 CCR1 Receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- SDMROTDUJNUWDR-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-[1-(1,3,4-thiadiazol-2-yl)cyclopropyl]pyrazolo[3,4-c]pyridine-4-carboxamide Chemical compound C1=CC(F)=CC=C1N1C2=CN=CC(C(=O)NC3(CC3)C=3SC=NN=3)=C2C=N1 SDMROTDUJNUWDR-UHFFFAOYSA-N 0.000 abstract 1
- JTXOGWNTNOJMLN-UHFFFAOYSA-N 1-(4-fluorophenyl)pyrazolo[3,4-c]pyridine-4-carboxylic acid Chemical compound N1=CC=2C(C(=O)O)=CN=CC=2N1C1=CC=C(F)C=C1 JTXOGWNTNOJMLN-UHFFFAOYSA-N 0.000 abstract 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 abstract 1
- UCLCFYOIAJQZNS-UHFFFAOYSA-N 4-[1-[[1-(4-fluorophenyl)pyrazolo[3,4-c]pyridine-4-carbonyl]amino]cyclopropyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1(NC(=O)C=2C=3C=NN(C=3C=NC=2)C=2C=CC(F)=CC=2)CC1 UCLCFYOIAJQZNS-UHFFFAOYSA-N 0.000 abstract 1
- XSNIKHRUAMUKOX-UHFFFAOYSA-N 6-cyano-1-(4-fluorophenyl)-n-[1-(2-methylsulfonylpyridin-4-yl)cyclopropyl]indazole-4-carboxamide Chemical compound C1=NC(S(=O)(=O)C)=CC(C2(CC2)NC(=O)C=2C=3C=NN(C=3C=C(C=2)C#N)C=2C=CC(F)=CC=2)=C1 XSNIKHRUAMUKOX-UHFFFAOYSA-N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- GGZZWHGHGJVJHU-UHFFFAOYSA-N n-[1-(5-bromopyrimidin-2-yl)cyclopropyl]-1-(4-fluorophenyl)pyrazolo[3,4-c]pyridine-4-carboxamide Chemical compound C1=CC(F)=CC=C1N1C2=CN=CC(C(=O)NC3(CC3)C=3N=CC(Br)=CN=3)=C2C=N1 GGZZWHGHGJVJHU-UHFFFAOYSA-N 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25359009P | 2009-10-21 | 2009-10-21 | |
| PCT/US2010/053142 WO2011049917A1 (en) | 2009-10-21 | 2010-10-19 | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599132A true NZ599132A (en) | 2014-05-30 |
Family
ID=43126891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599132A NZ599132A (en) | 2009-10-21 | 2010-10-19 | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9056858B2 (OSRAM) |
| EP (1) | EP2491028B1 (OSRAM) |
| JP (1) | JP5542946B2 (OSRAM) |
| KR (1) | KR20120087923A (OSRAM) |
| CN (1) | CN102666526A (OSRAM) |
| AP (1) | AP2012006204A0 (OSRAM) |
| AU (1) | AU2010308277A1 (OSRAM) |
| BR (1) | BR112012009331A2 (OSRAM) |
| CA (1) | CA2778060A1 (OSRAM) |
| CL (1) | CL2012000967A1 (OSRAM) |
| CO (1) | CO6531488A2 (OSRAM) |
| DK (1) | DK2491028T3 (OSRAM) |
| EA (1) | EA021015B1 (OSRAM) |
| EC (1) | ECSP12011904A (OSRAM) |
| ES (1) | ES2444780T3 (OSRAM) |
| GE (1) | GEP20146103B (OSRAM) |
| HR (1) | HRP20140213T1 (OSRAM) |
| IL (1) | IL218823A0 (OSRAM) |
| IN (1) | IN2012DN03449A (OSRAM) |
| MA (1) | MA33675B1 (OSRAM) |
| MX (1) | MX2012004644A (OSRAM) |
| NZ (1) | NZ599132A (OSRAM) |
| PE (1) | PE20121433A1 (OSRAM) |
| PH (1) | PH12012500775A1 (OSRAM) |
| PL (1) | PL2491028T3 (OSRAM) |
| PT (1) | PT2491028E (OSRAM) |
| RS (1) | RS53130B (OSRAM) |
| SI (1) | SI2491028T1 (OSRAM) |
| TN (1) | TN2012000180A1 (OSRAM) |
| WO (1) | WO2011049917A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5216912B2 (ja) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物 |
| CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| AP2739A (en) | 2008-09-26 | 2013-09-30 | Boehringer Ingelheim Int | Azaindazole compounds as CCRI receptor antagonists |
| CA2778060A1 (en) | 2009-10-21 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| JP5793182B2 (ja) | 2010-04-30 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物 |
| WO2012087782A1 (en) | 2010-12-23 | 2012-06-28 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
| CA2852160A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| ME03513B (me) | 2014-04-14 | 2020-04-20 | Boehringer Ingelheim Int | Jedinjenja kao modulatori za ror gama |
| CN112707831A (zh) * | 2021-02-05 | 2021-04-27 | 阿里生物新材料（常州）有限公司 | 一种3-（1-氨基环丙基）苯甲酸甲酯的合成方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1338625C (en) | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| JP2659107B2 (ja) | 1991-03-28 | 1997-09-30 | エーザイ株式会社 | 複素環式―環式アミン誘導体 |
| US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| RU2105005C1 (ru) | 1992-07-03 | 1998-02-20 | Кумиай Кемикал Индастри Ко., Лтд. | Конденсированное гетероциклическое производное, способ его получения и гербицидное средство |
| WO1995000509A1 (en) | 1993-06-25 | 1995-01-05 | Kumiai Chemical Industry Co., Ltd. | Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof |
| WO1996017842A1 (en) | 1994-12-06 | 1996-06-13 | Merck Sharp & Dohme Limited | Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists |
| GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| GB9523583D0 (en) | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| JP2000501105A (ja) | 1995-12-22 | 2000-02-02 | デュポン ファーマシューティカルズ カンパニー | 新規なインテグリン受容体アンタゴニスト |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| JPH101478A (ja) | 1996-06-11 | 1998-01-06 | Kumiai Chem Ind Co Ltd | インダゾールスルホニル尿素誘導体及び除草剤 |
| GB9615449D0 (en) | 1996-07-23 | 1996-09-04 | Merck Sharp & Dohme | Therapeutic agents |
| WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
| TR200001256T2 (tr) | 1997-11-04 | 2000-11-21 | Pfizer Products Inc. | Terapötik olarak aktif bileşimler. |
| US6331640B1 (en) | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| ATE303988T1 (de) | 1999-06-14 | 2005-09-15 | Lilly Co Eli | Inhibitoren von serin proteasen |
| AU5895500A (en) | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| ES2329754T3 (es) | 2000-03-02 | 2009-12-01 | Ndc Infrared Engineering Limited | Aparato de deteccion electromagnetica. |
| GB0030306D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030304D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030305D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| GB0030303D0 (en) | 2000-12-13 | 2001-01-24 | Lilly Co Eli | Compounds |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US7058826B2 (en) | 2000-09-27 | 2006-06-06 | Amphus, Inc. | System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment |
| US20020052373A1 (en) | 2000-10-26 | 2002-05-02 | Zorn Stevin H. | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| US20090286791A1 (en) | 2001-11-27 | 2009-11-19 | Takeda Pharmaceutical Company Limited | Amide Compounds |
| CA2478232C (en) | 2002-04-11 | 2011-06-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic amide derivatives as cytokine inhibitors |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| ATE438401T1 (de) | 2002-06-12 | 2009-08-15 | Chemocentryx Inc | 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen |
| CA2494942A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0203825D0 (sv) | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| JP2007502307A (ja) | 2003-08-15 | 2007-02-08 | アストラゼネカ アクチボラグ | グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環 |
| EP1855670A4 (en) | 2005-02-24 | 2010-05-05 | Merck Sharp & Dohme | BENZAZOLE AMPLIFIERS OF METABOTROPIC GLUTAMATE RECEPTORS |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| EP2444079B1 (en) | 2005-05-17 | 2016-11-30 | SARcode Bioscience Inc. | Compositions and Methods for Treatment of Eye Disorders |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| US7524845B2 (en) * | 2005-06-22 | 2009-04-28 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| BRPI0615048A2 (pt) | 2005-09-01 | 2010-03-30 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| US20080262040A1 (en) | 2005-10-25 | 2008-10-23 | Smithkline Beecham Corporation | Chemical Compounds |
| ES2547303T3 (es) | 2007-01-19 | 2015-10-05 | Ardea Biosciences, Inc. | Inhibidores de MEK |
| EP2170879B1 (en) * | 2007-06-26 | 2013-01-16 | AstraZeneca AB | 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors |
| JP2010535855A (ja) | 2007-08-10 | 2010-11-25 | クリスタルゲノミクス、インク． | ピリジン誘導体およびその使用方法 |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| KR20100101095A (ko) | 2007-11-29 | 2010-09-16 | 베링거 인겔하임 인터내셔날 게엠베하 | ６,７디하이드로５Ｈ이미다조[１,２α]이미다졸３카복실산 아미드의 유도체 |
| JP5216912B2 (ja) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物 |
| CA2722811C (en) | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| AP2739A (en) | 2008-09-26 | 2013-09-30 | Boehringer Ingelheim Int | Azaindazole compounds as CCRI receptor antagonists |
| CA2778060A1 (en) | 2009-10-21 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| IN2012DN05081A (OSRAM) | 2009-12-08 | 2015-10-09 | Boehringer Ingelheim Int | |
| JP5793182B2 (ja) | 2010-04-30 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物 |
| WO2012087782A1 (en) | 2010-12-23 | 2012-06-28 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
-
2010
- 2010-10-19 CA CA2778060A patent/CA2778060A1/en not_active Abandoned
- 2010-10-19 PH PH1/2012/500775A patent/PH12012500775A1/en unknown
- 2010-10-19 ES ES10768356.7T patent/ES2444780T3/es active Active
- 2010-10-19 BR BR112012009331A patent/BR112012009331A2/pt not_active IP Right Cessation
- 2010-10-19 EP EP10768356.7A patent/EP2491028B1/en active Active
- 2010-10-19 US US13/499,939 patent/US9056858B2/en active Active
- 2010-10-19 HR HRP20140213AT patent/HRP20140213T1/hr unknown
- 2010-10-19 PL PL10768356T patent/PL2491028T3/pl unknown
- 2010-10-19 KR KR1020127010143A patent/KR20120087923A/ko not_active Withdrawn
- 2010-10-19 EA EA201200602A patent/EA021015B1/ru not_active IP Right Cessation
- 2010-10-19 AP AP2012006204A patent/AP2012006204A0/xx unknown
- 2010-10-19 MX MX2012004644A patent/MX2012004644A/es active IP Right Grant
- 2010-10-19 PT PT107683567T patent/PT2491028E/pt unknown
- 2010-10-19 CN CN2010800578454A patent/CN102666526A/zh active Pending
- 2010-10-19 SI SI201030538T patent/SI2491028T1/sl unknown
- 2010-10-19 WO PCT/US2010/053142 patent/WO2011049917A1/en not_active Ceased
- 2010-10-19 RS RS20140024A patent/RS53130B/sr unknown
- 2010-10-19 JP JP2012535292A patent/JP5542946B2/ja active Active
- 2010-10-19 PE PE2012000493A patent/PE20121433A1/es not_active Application Discontinuation
- 2010-10-19 GE GEAP201012715A patent/GEP20146103B/en unknown
- 2010-10-19 IN IN3449DEN2012 patent/IN2012DN03449A/en unknown
- 2010-10-19 AU AU2010308277A patent/AU2010308277A1/en not_active Abandoned
- 2010-10-19 NZ NZ599132A patent/NZ599132A/en not_active IP Right Cessation
- 2010-10-19 DK DK10768356.7T patent/DK2491028T3/da active
-
2012
- 2012-03-25 IL IL218823A patent/IL218823A0/en unknown
- 2012-04-16 MA MA34779A patent/MA33675B1/fr unknown
- 2012-04-16 CL CL2012000967A patent/CL2012000967A1/es unknown
- 2012-04-19 TN TNP2012000180A patent/TN2012000180A1/en unknown
- 2012-04-26 CO CO12068976A patent/CO6531488A2/es active IP Right Grant
- 2012-05-16 EC ECSP12011904 patent/ECSP12011904A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599132A (en) | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists | |
| MY167791A (en) | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists | |
| PE20110854A1 (es) | DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1 | |
| GEP201706774B (en) | Heterocyclyl compounds | |
| NZ607638A (en) | Novel compounds and compositions for the inhibition of nampt | |
| EA201171008A1 (ru) | Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы | |
| EA200901379A1 (ru) | Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа | |
| PH12012502334A1 (en) | Heteroaryl imidazolone derivatives as jak inhibitors | |
| MX2013005008A (es) | Derivados de carboxamida y urea heteroaromaticos sustituidos como ligandos del receptor vanilloide. | |
| TW200621729A (en) | Pyrimidine derivatives | |
| NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
| TNSN07074A1 (en) | Pyrimidine derivatives | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| TW200732323A (en) | Organic compounds | |
| WO2011101069A3 (en) | 1, 8 -naphthyridines as kinase inhibitors | |
| MX349156B (es) | Formas cristalinas y procesos para la preparacion de fenil-pirazoles utiles como moduladores del receptor de serotonina 5-ht2a. | |
| WO2011042860A3 (en) | New derivatives of thieno[2,3-b]pyridine and 5,6,7,8-tetrahydrothieno[2,3-b]quinoline in particular useful in the treatment of malaria | |
| NZ597538A (en) | Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives | |
| MX2010004498A (es) | Derivados de ciclohexenoamida y su uso como antagonistas de trpv1. | |
| MX2009007429A (es) | Compuestos de piridina y su uso como antagonistas de p2y12. | |
| MX354014B (es) | Amidas de compuestos de 2-amino-4-ariltiazol y sus sales. | |
| TW200606153A (en) | Process for producing pyridine derivatives of Nk-1 receptor antagonist | |
| TW200833333A (en) | New pyridine analogues | |
| MX353994B (es) | Formas polimorfas. | |
| NO20063562L (no) | Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |